GAITHERSBURG, Md., June 4, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, announced the presentation of positive clinical data from the first 12 evaluable patients treated in the ongoing Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed and refractory multiple myeloma. The results were presented today at

Novel synthetic binding domain used in CART-ddBCMA demonstrates potent anti-tumor activity Results underpin Arcellx’s ongoing first-in-human Phase 1 CART-ddBCMA trial in patients with relapsed and refractory multiple myeloma GAITHERSBURG, Md., May 13, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced the presentation of preclinical data of CART-ddBCMA, Arcellx’s BCMA-specific

GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs and Neeraj Teotia

GAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase

GAITHERSBURG, Md., April 6, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma. ACLX-001 is the first clinical application of the

GAITHERSBURG, Md., Jan. 26, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced the appointment of Rami Elghandour as Chairman of the Board and Chief Executive Officer, effective Jan. 22, 2021. Arcellx’s founder and CEO, David Hilbert, Ph.D., will transition to the new role

Company announces initial results in first-in-human trial utilizing novel synthetic binding domain 6/6 (100%) overall response rate (ORR) per International Myeloma Working Group (IMWG) criteria observed at Dose Level 1 GAITHERSBURG, Md., Dec. 07, 2020 (GLOBE NEWSWIRE) – – Arcellx, a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced initial clinical data

GAITHERSBURG, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) – – Arcellx today announced that clinical data from its ongoing Phase 1 Study of CART-ddBCMA, a genetically engineered cell therapy utilizing the company’s novel synthetic binding domain for the treatment of patients with relapsed and refractory multiple myeloma, will be presented at the 62nd American Society of

GAITHERSBURG, Md., Oct. 02, 2020 (GLOBE NEWSWIRE) — Arcellx today announced that David Hilbert, Chief Executive Officer, will present at the following upcoming investor conference. Presentation Details: Event: Jefferies Virtual Cell Therapy Summit Date: Monday, Oct. 5, 2020 Time: 4:30 p.m. ET To view the live presentation, click here: https://wsw.com/webcast/jeff146/arce/1823250 About Arcellx’s ARC-sparX Platform Technology

Gaithersburg, Md. – August 24, 2020 – Arcellx today announced the award of an EvansMDS Discovery Research Grant to Johns Hopkins University to support development of an Arcellx ARC-sparX therapy in the treatment of high-risk myelodysplastic syndromes (MDS). The collaborative effort, led by Amy E. DeZern, M.D., at the Johns Hopkins University School of Medicine,

Dr. Sklavos joins Arcellx with over 15 years of experience in biomedical and clinical research in academic, government, and industry settings. Dr. Sklavos brings broad drug development expertise to Arcellx as a result of managing multiple complex projects and portfolios comprised of various drug modalities including monoclonal and bispecific antibodies, antibody-drug conjugates, peptide conjugates, and

Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases, today presented preclinical data demonstrating the utility of its ARC-sparX platform technology as directed against the CD123 antigen, a therapeutic target for hematologic malignancies including acute myelogenous leukemia (AML). The data show that

Gaithersburg, Md. – June 2, 2020 – Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases, today announced that David Hilbert, Chief Executive Officer, will present at the following upcoming investor conference. Presentation Details: Event: Jefferies Virtual Healthcare Conference Date: Thursday, June

Gaithersburg, Md. – May 19, 2020 – Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases, today announced that Han Lee, Chief Financial Officer, will present at the following upcoming investor conference. Presentation Details: Event: UBS Virtual Global Healthcare Conference Date: Wednesday,

Gaithersburg, Md. – May 13, 2020 – Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases, today announced that it will present at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually May 29-31, 2020. The presentation details

Gaithersburg, Md. – April 29, 2020 – Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases, today announced that it will present at the 2020 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place in a virtual format May

GAITHERSBURG, Md., March 12, 2020 (GLOBE NEWSWIRE) — Arcellx, a clinical-stage biopharmaceutical company devoted to developing immune cell therapies for cancer and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CART-ddBCMA, its engineered T cell therapy utilizing a novel binding domain, for the treatment of

Gaithersburg, Md. – Feb. 28, 2020 – Arcellx today announced that the first patient has been dosed with its engineered T cell therapy utilizing a novel deimmunized synthetic binding domain in the treatment of patients with relapsed and refractory multiple myeloma. This first-in-human Phase 1 trial is the first in a series of clinical trials

Gaithersburg, Md. – Oct. 3, 2019 – Arcellx, a privately-held biopharmaceutical company, today announced that it has raised $85 million in an oversubscribed Series B financing. Proceeds will be used to advance the Company’s ARC-T + sparX programs, including clinical development of a bivalent BCMA-targeted cell therapy in multiple myeloma, and a CD123-targeted therapy in